HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to tackle tough leukemia
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin, which targets and kills leukemia cells, combined with low-intensity chemotherapy. It is for adults with acute lymphoblastic leukemia (ALL), including those who are older or whose cancer has returned. The goal is to find the be…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:13 UTC
-
New CAR T-Cell therapy targets tough lymphoma cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
New hope for aggressive lymphoma: targeted drug combo under study
Disease control Recruiting nowThis early-phase study tests whether adding the targeted drug polatuzumab vedotin (with or without another drug, glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to see how well …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
New combo therapy hopes to boost lymphoma treatment
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 participants will receive the combination as their first treatment. The goal is to improve cancer remissi…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 20, 2026 11:56 UTC